ReviewNanomedicine (London, England)2025
Research progress on mRNA drug delivery strategies in the nervous system.
Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Functionalized Lipid Nanoparticles for Targeted RNA Delivery in Immune and Inflammatory Diseases.Biomedicines · 2026Review
- Global landscape of mRNA vaccine clinical trials: a systematic analysis of ClinicalTrials.gov data.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There has been little progress in the treatment of central nervous system (CNS) disorders in recent decades. To date, new therapeutic agents such as small molecule drugs, cytokines, monoclonal antibodies and vaccines targeting specific antigens are still in the research and development stage and have not yet entered clinical use. With the discovery of gene-editing technology and the development of new therapeutic strategies, mRNA has been developed and used as a new type of drug, showing potential application value in the treatment of various neurological diseases. However, mRNA drugs face difficulties in being delivered to the CNS to exert therapeutic effects. We conducted a review by searching the PubMed database for relevant literature up to now, focusing on the research progress of mRNA drug delivery systems in the nervous system and their applications in neurological diseases, explore the challenges and prospects of mRNA drugs in neurological diseases, and provide reference for the development and implementation of mRNA drugs for neurological diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.